Home » Drug Information » FDA-Approved Drugs » 1996
Medical Areas: Pulmonary/Respiratory Diseases
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Boehringer Ingelheim
Approval Status: Approved January 1996
Treatment Area: runny nose due to allergies and the common cold
Atrovent nasal spray has been approved as treatment for a runny
nose caused by allergies or the common cold. Atrovent nasal spray
is not indicated for the relief of sneezing, congestion, or
postnasal drip.
Atrovent comes in two strengths: 0.3% for runny nose associated
with the allergic and nonallergic conditions, and .06% for the
common cold.
Atrovent has been shown to be effective both acutely, in
controlled common cold studies of up to four days duration, and in
controlled perennial rhinitis trials of eight weeks duration.
In clinical trials, Atrovent was well tolerated and has been
shown to have minimal side effects such as transient nasal dryness
and epistaxis (nasal bleeding) in less than 10% of patients.
There are many factors related to allergies and colds that
contribute to a runny nose. These factors stimulate the release of
acetylcholine, which in turn, stimulates the glands in the nose,
causing watery secretions. Atrovent blocks the effect of
acetylcholine.
